246 related articles for article (PubMed ID: 20424599)
1. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs.
Haurigot V; Mingozzi F; Buchlis G; Hui DJ; Chen Y; Basner-Tschakarjan E; Arruda VR; Radu A; Franck HG; Wright JF; Zhou S; Stedman HH; Bellinger DA; Nichols TC; High KA
Mol Ther; 2010 Jul; 18(7):1318-29. PubMed ID: 20424599
[TBL] [Abstract][Full Text] [Related]
2. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
[TBL] [Abstract][Full Text] [Related]
3. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
[TBL] [Abstract][Full Text] [Related]
4. Persistent expression of canine factor IX in hemophilia B canines.
Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
[TBL] [Abstract][Full Text] [Related]
5. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
Manno CS; Chew AJ; Hutchison S; Larson PJ; Herzog RW; Arruda VR; Tai SJ; Ragni MV; Thompson A; Ozelo M; Couto LB; Leonard DG; Johnson FA; McClelland A; Scallan C; Skarsgard E; Flake AW; Kay MA; High KA; Glader B
Blood; 2003 Apr; 101(8):2963-72. PubMed ID: 12515715
[TBL] [Abstract][Full Text] [Related]
6. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
High KA
Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
[TBL] [Abstract][Full Text] [Related]
7. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
Buchlis G; Podsakoff GM; Radu A; Hawk SM; Flake AW; Mingozzi F; High KA
Blood; 2012 Mar; 119(13):3038-41. PubMed ID: 22271447
[TBL] [Abstract][Full Text] [Related]
8. AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Hasbrouck NC; High KA
Gene Ther; 2008 Jun; 15(11):870-5. PubMed ID: 18432276
[TBL] [Abstract][Full Text] [Related]
9. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
[TBL] [Abstract][Full Text] [Related]
10. Muscle as a target for supplementary factor IX gene transfer.
Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
[TBL] [Abstract][Full Text] [Related]
12. AAV-mediated gene transfer for hemophilia.
High KA
Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
[TBL] [Abstract][Full Text] [Related]
13. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
[TBL] [Abstract][Full Text] [Related]
14. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
Liu YL; Mingozzi F; Rodriguéz-Colôn SM; Joseph S; Dobrzynski E; Suzuki T; High KA; Herzog RW
Hum Gene Ther; 2004 Aug; 15(8):783-92. PubMed ID: 15319035
[TBL] [Abstract][Full Text] [Related]
16. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
[TBL] [Abstract][Full Text] [Related]
17. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.
Rogers GL; Martino AT; Zolotukhin I; Ertl HC; Herzog RW
J Transl Med; 2014 Jan; 12():25. PubMed ID: 24460861
[TBL] [Abstract][Full Text] [Related]
18. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
[TBL] [Abstract][Full Text] [Related]
19. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
Kay MA; Manno CS; Ragni MV; Larson PJ; Couto LB; McClelland A; Glader B; Chew AJ; Tai SJ; Herzog RW; Arruda V; Johnson F; Scallan C; Skarsgard E; Flake AW; High KA
Nat Genet; 2000 Mar; 24(3):257-61. PubMed ID: 10700178
[TBL] [Abstract][Full Text] [Related]
20. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors.
Wang L; Louboutin JP; Bell P; Greig JA; Li Y; Wu D; Wilson JM
J Thromb Haemost; 2011 Oct; 9(10):2009-19. PubMed ID: 21883883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
